Part 1 of this series on Operation Warp Speed and Race, “The Johns Hopkins, CDC Plan to Mask Medical Experimentation on Minorities as ‘Racial Justice,’” explored Warp Speed’s vaccine allocation plan in depth. That plan utilizes a phased approach aimed at “populations of focus” that had been identified in advance by various government organizations, including the CDC’s Advisory Committee on Immunization Practices.
The main focus of this allocation strategy is to deliver vaccines first to racial minorities and in such a way as to make them feel “at ease” and not like “guinea pigs.” This is particularly glaring given that these minorities will be receiving an experimental vaccine that allocation-strategy documents admit is likely to cause “certain adverse effects . . . more frequently in certain population subgroups,” with research showing that those “subgroups” most at risk of experiencing adverse effects are these same racial minorities.
The fact that the Florida Department of Health is taking this step is a sign that an increasing number of health professionals and regulators are questioning the accuracy of the PCR test. The PCR is the most common lab test being used to detect COVID-19. This incredibly sensitive technique was developed by Berkeley scientist Kary Mullis, for which he was awarded the Nobel Prize in 1993. The test is designed to detect the presence of a virus by amplifying the virus’ genetic material so it can be detected by scientists. The test is viewed as the gold standard, however, it is not without problems.
